L-744832 | CAS#160141-09-3 | CAS#1177806-11-9 | Farnesyltransferase inhibitor

MedKoo Cat#: 406301 | Name: L-744832

Description:

WARNING: This product is for research use only, not for human or veterinary use.

L-744832, also known as L-744,832, is a potent Farnesyltransferase inhibitor with potential anticancer activity.

Chemical Structure

L-744832

CAS#160141-09-3

Theoretical Analysis

MedKoo Cat#: 406301

Name: L-744832

CAS#: 160141-09-3

Chemical Formula: C26H45N3O6S2

Exact Mass: 559.2750

Molecular Weight: 559.78

Elemental Analysis: C, 55.79; H, 8.10; N, 7.51; O, 17.15; S, 11.46

Price and Availability

Size	Price	Availability	Quantity

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

L744832; L 744832; L-744832

IUPAC/Chemical Name

(S)-isopropyl 2-((S)-2-(((2S,3S)-2-(((R)-2-amino-3-mercaptopropyl)amino)-3-methylpentyl)oxy)-3-phenylpropanamido)-4-(methylsulfonyl)butanoate

InChi Key

PGOKBMWPBDRDGN-IBXSQZDTSA-N

InChi Code

InChI=1S/C26H45N3O6S2/c1-6-19(4)23(28-15-21(27)17-36)16-34-24(14-20-10-8-7-9-11-20)25(30)29-22(12-13-37(5,32)33)26(31)35-18(2)3/h7-11,18-19,21-24,28,36H,6,12-17,27H2,1-5H3,(H,29,30)/t19-,21+,22-,23+,24-/m0/s1

SMILES Code

O=C(OC(C)C)[C@@H](NC([C@@H](OC[C@@H](NC[C@@H](N)CS)[C@@H](C)CC)CC1=CC=CC=C1)=O)CCS(=O)(C)=O

Appearance

Solid powder

Purity

>98%

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>5 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

L-744832, also known as L-744,832, is a potent Farnesyltransferase inhibitor with potential anticancer activity.

In vitro activity:

Administration of L-744,832, neither alone nor its combination with 5-FU and radiation, affected the number of DLD-1 cells and apoptosis rates. Regarding its effects on the cell cycle, L-744,832 was shown to lead to G(0)/G(1) and G(2)/M accumulation in a dose-dependent manner when administered alone. However, in combination with 5-FU, only a G(0)/G(1) accumulation was observed. Reference: Chemotherapy. 2005 Oct;51(6):319-23. https://pubmed.ncbi.nlm.nih.gov/16224182/

In vivo activity:

In syngeneic mice transplanted with the transgenic lymphoma cells, L-744,832 treatment prevented the growth of the tumor cells and the morbidity associated with the resulting lymphoma progression. Tumors that arose from transplantation of the lymphoma cells regressed with as little as three days of treatment with L-744,832 or SCH66336. Treatment of these established lymphomas with L-744,832 for seven days led to long-term remission of the disease in approximately 25% of animals. Reference: Mol Cancer. 2008 May 19;7:39. https://pubmed.ncbi.nlm.nih.gov/18489761/

Preparing Stock Solutions

The following data is based on the product molecular weight 559.78 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Kavgaci H, Ozdemir F, Ovali E, Yavuz A, Yavuz M, Aydin F. Effect of the farnesyl transferase inhibitor L-744,832 on the colon cancer cell line DLD-1 and its combined use with radiation and 5-FU. Chemotherapy. 2005 Oct;51(6):319-23. doi: 10.1159/000088954. Epub 2005 Oct 13. PMID: 16224182. 2. Kopec M, Strusinska K, Legat M, Makowski M, Jakobisiak M, Golab J. Potentiated antitumor effects of a combination therapy with a farnesyltransferase inhibitor L-744,832 and butyrate in vitro. Oncol Rep. 2004 May;11(5):1127-31. PMID: 15069557. 3. Gaylo AE, Laux KS, Batzel EJ, Berg ME, Field KA. Delayed rejection of MHC class II-disparate skin allografts in mice treated with farnesyltransferase inhibitors. Transpl Immunol. 2009 Jan;20(3):163-70. doi: 10.1016/j.trim.2008.09.011. Epub 2008 Oct 18. PMID: 18930822; PMCID: PMC7369389. 4. Field KA, Charoenthongtrakul S, Bishop JM, Refaeli Y. Farnesyl transferase inhibitors induce extended remissions in transgenic mice with mature B cell lymphomas. Mol Cancer. 2008 May 19;7:39. doi: 10.1186/1476-4598-7-39. PMID: 18489761; PMCID: PMC2409375.

In vitro protocol:

In vivo protocol:

1. Gaylo AE, Laux KS, Batzel EJ, Berg ME, Field KA. Delayed rejection of MHC class II-disparate skin allografts in mice treated with farnesyltransferase inhibitors. Transpl Immunol. 2009 Jan;20(3):163-70. doi: 10.1016/j.trim.2008.09.011. Epub 2008 Oct 18. PMID: 18930822; PMCID: PMC7369389. 2. Field KA, Charoenthongtrakul S, Bishop JM, Refaeli Y. Farnesyl transferase inhibitors induce extended remissions in transgenic mice with mature B cell lymphomas. Mol Cancer. 2008 May 19;7:39. doi: 10.1186/1476-4598-7-39. PMID: 18489761; PMCID: PMC2409375.

1: Spindler SR, Li R, Dhahbi JM, Yamakawa A, Mote P, Bodmer R, Ocorr K, Williams RT, Wang Y, Ablao KP. Statin treatment increases lifespan and improves cardiac health in Drosophila by decreasing specific protein prenylation. PLoS One. 2012;7(6):e39581. doi: 10.1371/journal.pone.0039581. Epub 2012 Jun 21. PubMed PMID: 22737247; PubMed Central PMCID: PMC3380867. 2: Murphy LA, Moore T, Nesnow S. Propiconazole-enhanced hepatic cell proliferation is associated with dysregulation of the cholesterol biosynthesis pathway leading to activation of Erk1/2 through Ras farnesylation. Toxicol Appl Pharmacol. 2012 Apr 15;260(2):146-54. doi: 10.1016/j.taap.2012.02.003. Epub 2012 Feb 14. PubMed PMID: 22361350.